Evidence map›Paper›PMID 41025079›Full record

ArticleWorld journal of gastroenterology2025

Peroxiredoxin 1 inhibits tumorigenesis by activating the NLRP3/GSDMD pathway to induce pyroptosis of colorectal cancer cells.

Ying He, Jing Liu, Ning Zhou, Ling-Xiang Xie, Yong-Fang Jiang, Chun-Lan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying HeDepartment of Infectious Diseases, The Second Xiangya Hospital of Central South University, Clinical Medical Research Center for Viral Hepatitis in Hunan Province, Changsha 410011, Hunan Province, China.
Jing LiuDepartment of Infectious Diseases, The Second Xiangya Hospital of Central South University, Clinical Medical Research Center for Viral Hepatitis in Hunan Province, Changsha 410011, Hunan Province, China.
Ning ZhouDepartment of Infectious Diseases, The Second Xiangya Hospital of Central South University, Clinical Medical Research Center for Viral Hepatitis in Hunan Province, Changsha 410011, Hunan Province, China.
Ling-Xiang XieNational Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Yong-Fang JiangDepartment of Infectious Diseases, The Second Xiangya Hospital of Central South University, Clinical Medical Research Center for Viral Hepatitis in Hunan Province, Changsha 410011, Hunan Province, China.
Chun-Lan ChenDepartment of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410005, Hunan Province, China. cclen208@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDamage associated molecular patterns (DAMPs) are vital for the immunogenic cell death of cancer cells and can enhance the anti-tumor activity of immune cells in colorectal cancer (CRC). Peroxiredoxin 1 (Prdx1), an important DAMP, is highly expressed in various tumor tissues including CRC. However, the role of Prdx1 in CRC remains unknown.

aimTo investigate the effect and mechanisms of Prdx1 on CRC.

methodsPatients diagnosed with CRC in our medical center were included in this study to verify the expression of Prdx1 in cancer tissues. Recombinant Prdx1 (rPrdx1) was used to stimulate RKO and SW480 colon cancer cells. The cell survival rate, migration, proliferation and invasion ability were assessed. Transmission electron microscopy, TUNEL assay, lactate dehydrogenase release assay, and Western blot were used to determine the effect of Prdx1 on pyroptosis. NLRP3 inflammasome inhibitor and gasdermin D (GSDMD) inhibitor were used to explore the mechanism of Prdx1-induced pyroptosis.

resultsThe mRNA and protein levels of Prdx1 were significantly increased in the tumor tissues of patients with CRC. rPrdx1 inhibited the viability, proliferation, migration and invasion of RKO and SW480 colon cancer cells. Further study found that rPrdx1 inhibited the malignant biological behaviors of CRC cells by inducing pyroptosis rather than apoptosis and necroptosis. Mechanistically, rPrdx1 induces pyroptosis of CRC cells by activating the NLRP3 inflammasome/GSDMD pathway.

conclusionPrdx1 induces pyroptosis by activating the NLRP3 inflammasome/GSDMD pathway, thereby inhibiting the malignant biological behavior of RKO and SW480 colon cancer cells.

Indexed as

CarcinogenesisColorectal NeoplasmsIntracellular Signaling Peptides and ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinPeroxiredoxinsPyroptosisCell Line, TumorCell MovementCell ProliferationFemaleGasderminsGene Expression Regulation, NeoplasticHumansInflammasomesMaleMiddle AgedGasderminsGSDMD protein, humanInflammasomesIntracellular Signaling Peptides and ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanPeroxiredoxinsPhosphate-Binding ProteinsPRDX1 protein, humanColorectal cancerDamage associated molecular patternsGasdermin DPeroxiredoxin 1Pyroptosis

Identifiers

PMID41025079
PMCPMC12476671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.